Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-03

Clinical Trial Update: Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results update on intermittent degarelix treatment for prostate cancer; the study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-09-03